Vimian Group AB (publ) (STO:VIMIAN)

Market Cap	21.14B
Revenue (ttm)	4.29B
Net Income (ttm)	211.97M
Shares Out	523.89M
EPS (ttm)	0.42
PE Ratio	95.91
Forward PE	32.92
Dividend	n/a
Ex-Dividend Date	n/a

Volume	237,710
Average Volume	375,525
Open	39.95
Previous Close	40.35
Day's Range	39.80 - 40.85
52-Week Range	28.40 - 47.30
Beta	1.58
RSI	53.73
Earnings Date	Apr 29, 2025

About Vimian Group AB

Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the I...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2020
• Employees: 1,200
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: VIMIAN

Financial Performance

In 2024, Vimian Group AB's revenue was 374.80 million, an increase of 12.99% compared to the previous year's 331.70 million. Earnings were 18.50 million, an increase of 88.78%.

Financial numbers in EUR